Dong OM. Using the diffusion of innovation theory to understand the challenges and opportunities to advancing use of nutrigenetics in clinical practice. Lifestyle Genom. 2021 Dec;14(4):124-8. doi: 10.1159/000517760
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, Macgillivray T. Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019 Jul 1;64(4):498-511. doi: 10.1016/j.survophthal.2019.02.003
Zeisel SH, Niculescu MD, Meyer KA, Dong OM, Chmurzynska A, Kohlmeier M. Precision nutrition. A nutrigenetic-based framework to establish guidelines for choline intake. Presented at the 2019 Congress of the International Society of Nutrigenetics & Nutrigenomics; July 13, 2019. Cambridge, United Kingdom. [abstract] Lifestyle Genom. 2018; 11:178. doi: 10.1159/000501177
Dong OM. Pharmaconutrigenetics of antipsychotic-induced weight gain. Presented at the Congress of the International Society of Nutrigenetics & Nutrigenomics; July 12, 2019. Cambridge, UK. [abstract] Lifestyle Genom. 2018; 11.
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Odom D, Mladsi D, Purser M, Kaye JA, Palaka E, Charter A, Jensen JA, Sellami D. A matching-adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. J Skin Cancer. 2017;2017:6121760. doi: 10.1155/2017/6121760
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.